Busy end of the year for our group

Janne Reseland and Petter Lyngstadaas participated at the kick-off meeting for yet another European project last week

From left; Joseph Lorang, Janne E Reseland, Ståle Petter Lyngstadaas, Alain petit, Didier Ritter, Anaïs Vaissière.

The kick-off meeting for the project OralG  took place in Montpellier, France November 28-29. This European project is co-funded by EUREKA member countries and the European Union under the  Horizon 2020 Framework Programme. The partners in the OralG project is two companies,  Régentis-pharma and  Corticalis As and one academic partner Institute of Clinical Dentistry, UiO.

Present at the kick-off meeting was Alain Petit, founder and CEO of Vivaligne Company, Didier Ritter and Anaïs Vaissière, (Régentis-Pharma), Ståle Petter Lyngstadaas (Corticalis), and Janne E.  Reseland (UiO). Joseph Lorang (LORANG) is in charge of the management of the OralG project.

The aim of the project is to develop a medical device (MD) based on a new patented synthetic bifunctional peptide acting as a non-antibiotic, anti inflammatory wound healing agent for protections against severe periodontitis and peri-implantitis. Unmet medical needs regarding oral soft tissue management are specifically targeted. Thanks to a new gel against inflammation, avoiding loss of jaw-bone and painful regenerative procedures for patients and costs for both patients and public stakeholders.

Published Dec. 13, 2018 8:00 AM - Last modified Jan. 15, 2019 1:30 PM